EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

  • December 2016 •
  • 99 pages •
  • Report ID: 4584199 •
  • Format: PDF
EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

Summary

Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system (ACS, 2016a; IARC, 2014). Non-invasive (stage 0) types of breast cancer also exist, with the most common type being ductal carcinoma in situ (DCIS) (ACS, 2016a). DCIS refers to abnormal cells that are present in the breast ducts, but have not invaded through duct walls into the surrounding breast tissue (ACS, 2016a).

According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent (IARC, 2014). Prolonged exposure to endogenous and exogenous sex hormones; gene mutations; a family history of breast cancer; overweightness and obesity; physical inactivity; a sedentary lifestyle; high alcohol consumption; early age at menarche (younger than 12 years); late age at menopause (older than 55 years); and clinical factors, such as biopsy-confirmed atypical hyperplasia and having a high breast tissue and bone density, are all risk factors for breast cancer (ACS, 2011).

Epidemiologists forecast that the diagnosed incident cases of invasive breast cancer (not including DCIS) in the 8MM for women will grow by an Annual Growth Rate (AGR) of 1.94% over the next 10 years, from 795,114 cases in 2015 to 949,161 cases in 2025. In 2015, the 60–69 year age group had the highest number of diagnosed incident cases of invasive breast cancer, contributing 195,701 (24.61%) cases of the total in the 8MM. Overall, the majority of diagnosed incident cases of breast cancer occurred in ages 40 years and older, accounting for 95.48% of all cases in the 8MM in 2015.

The 8MM will see an increase in five-year diagnosed prevalent cases throughout the forecast period at an AGR of 2.39%, with 3,549,784 cases in 2015 and 4,399,243 in 2025. For HER2 status of diagnosed incident cases of invasive breast cancer in the 8MM throughout the forecast period, 17.53% of cases were HER2+, 68.07% were HER2-/HR+, and 14.40% were TN. For initial stage at diagnosis throughout the forecast period, 37.82% of diagnosed incident cases of invasive breast cancer were in stage I, 43.19% were in stage II, 14.59% were in stage III, and 4.40% were in stage IV, in the 8MM.

The report “EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025” provide an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). This report includes a forecast of non-invasive ductal carcinoma in situ (DCIS) breast cancer cases segmented by HER2 status. In addition, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of invasive breast cancer in women segmented by age (18 to 85 years and older) and HER2 status (HER2+/hormone receptor [HR]+, HER2+/HR-, HER2-/HR+, and HER2-/HR- triple negative [TN]). HER2+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and site of metastasis; HER2-/HR+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and biomarker expression; and TN invasive breast cancer cases are further segmented by stage at diagnosis and BRCA expression.

Scope

- The Breast Cancer EpiCast Report provides an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). This report includes a forecast of non-invasive ductal carcinoma in situ (DCIS) breast cancer cases segmented by HER2 status. In addition, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of invasive breast cancer in women segmented by age (18 to 85 years and older) and HER2 status (HER2+/hormone receptor [HR]+, HER2+/HR-, HER2-/HR+, and HER2-/HR- triple negative [TN]). HER2+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and site of metastasis; HER2-/HR+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and biomarker expression; and TN invasive breast cancer cases are further segmented by stage at diagnosis and BRCA expression.
- The breast cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Breast Cancer EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
- Quantify patient populations in the global breast cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for breast cancer therapeutics in each of the markets covered.
- Compare patient population potentials by HER2 status, menopausal status, and biomarker expression
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.